The Retina Case Forum Webinar Series is an interactive web-based virtual meeting place for healthcare practitioners to review current concepts within retina. Each live webinar allows for peer-to-peer presentation with the creation of a comprehensive differential diagnosis, the interpretation of the results of diagnostic tests, and an exploration of the potential therapeutic options by identifying the advantages and drawbacks of each approach. Pre and post testing will allow for meaningful recognition of educational goals. The discussions will be of interest to retina specialists, comprehensive ophthalmologists, residents and fellows in training, and allied health professionals.

Uveitis Cases

  • Burden of Treatment in Non Infectious Uveitis

    Steven Yeh, MD
  • New and Emerging Therapies for Uveitis: Beyond Steroids

    Pauline Merrill, MD
  • Uveitis Question and Answer Session

    Steven Yeh, MD & Pauline Merrill, MD
Launch Date

October 20, 2016

Expiration Date

October 20, 2017

Estimated Time to Complete

1 Hour

Hardware/Software Needed to Participate

High speed internet access

Target Audience

This activity is designed to meet the educational need of retina specialists, comprehensive ophthalmologists, residents and fellows in training , and allied healthcare professionals involved in the care of patients with retinal diseases such as diabetic retinopathy.

Learning Objectives

After completing this activity, the participant should be better able to:

    • Identify the burden of treatment in non-infectious uveitis.
    • Discuss results of recent clinical trials of new treatments for non-infectious uveitis affecting the posterior segment.
Method of Participation

In order to receive credit, participants should watch the entire video. Statements of credit will be awarded upon successful completion of the post test and online evaluation/claim credit form. If you have questions about this CME activity, please contact AKH Inc. at


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and MCME Global, Inc. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty Disclosures

Pauline Merrill, MD

  • Consultant: AbbVie Inc.; Santen Pharmaceutical

Steven Yeh, MD

  • Consultant: Clearside Biomedical; Santen Pharmaceutical
Planner Disclosures

Dorothy Caputo, MA, BSN, RN- CE Director of Accreditations

  • Nothing to Disclose

MCME Global Staff and Planners

  • Nothing to Disclose

AKH Staff and Planners

  • Nothing to Disclose
Commercial Support

This activity is supported by and educational grant from: Alcon, Inc.; Alimera Sciences; Allergan; Carl Zeiss; Optos; Regeneron Pharmaceuticals, Inc.; Santen Pharmaceutical


It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Author Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other author for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

Disclosure of Unlabeled Use of Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.

Jointly provided by AKH Inc., Advancing Knowledge in Healthcare and MCME Global, Inc.

Advancing Knowledge in Healthcare    mcme-logo

This activity is supported by educational grants from:

Alimera Sciences
Regeneron Pharmaceuticals, Inc.
Santen Pharmaceutical

First Name*
Last Name*

Which of the following sequelae may be observed with melanoma immunotherapy?

Anterior Uveitis
All of the above

Risks of intravitreal sirolimus for uveitis include:

High rate of glaucoma
High rate of cataract progression
Increased intraocular inflammation
Increased risk of systemic malignancy